Raymond James & Associates Pacira Bio Sciences, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	BUY	$27.7 - $35.48 $309,132 - $395,956	11,160 Added 58.69%	30,175 $881,000
Q4 2023 Jan 16, 2024	SELL	$26.32 - $34.31 $88,014 - $114,732	-3,344 Reduced 14.96%	19,015 $641,000
Q3 2023 Oct 24, 2023	SELL	$30.68 - $40.09 $519,964 - $679,445	-16,948 Reduced 43.12%	22,359 $685,000
Q2 2023 Jul 25, 2023	SELL	$36.12 - $47.5 $18,493 - $24,320	-512 Reduced 1.29%	39,307 $1.58 Million
Q1 2023 Apr 14, 2023	SELL	$35.53 - $43.38 $1,385 - $1,691	-39 Reduced 0.1%	39,819 $1.63 Million
Q4 2022 Feb 08, 2023	BUY	$38.19 - $57.45 $162,727 - $244,794	4,261 Added 11.97%	39,858 $1.54 Million
Q3 2022 Oct 25, 2022	SELL	$51.24 - $58.89 $178,776 - $205,467	-3,489 Reduced 8.93%	35,597 $1.89 Million
Q2 2022 Aug 12, 2022	BUY	$51.49 - $81.64 $194,992 - $309,170	3,787 Added 10.73%	39,086 $2.28 Million
Q1 2022 May 11, 2022	BUY	$60.03 - $76.49 $47,483 - $60,503	791 Added 2.29%	35,299 $2.69 Million
Q4 2021 Feb 08, 2022	BUY	$47.97 - $62.21 $182,286 - $236,398	3,800 Added 12.37%	34,508 $2.08 Million
Q3 2021 Nov 02, 2021	BUY	$54.64 - $61.3 $105,400 - $118,247	1,929 Added 6.7%	30,708 $1.72 Million
Q2 2021 Aug 11, 2021	SELL	$59.18 - $69.99 $25,092 - $29,675	-424 Reduced 1.45%	28,779 $1.75 Million
Q1 2021 May 14, 2021	BUY	$59.31 - $78.82 $1.45 Million - $1.92 Million	24,365 Added 503.62%	29,203 $2.05 Million
Q4 2020 Feb 12, 2021	SELL	$50.47 - $66.26 $123,348 - $161,939	-2,444 Reduced 33.56%	4,838 $290,000
Q3 2020 Nov 04, 2020	BUY	$51.97 - $63.0 $129,717 - $157,248	2,496 Added 52.15%	7,282 $438,000
Q2 2020 Jul 28, 2020	SELL	$30.8 - $52.47 $79,125 - $134,795	-2,569 Reduced 34.93%	4,786 $251,000
Q1 2020 Apr 21, 2020	SELL	$28.4 - $50.7 $41,407 - $73,920	-1,458 Reduced 16.54%	7,355 $247,000
Q4 2019 Feb 12, 2020	BUY	$36.31 - $46.83 $72,620 - $93,660	2,000 Added 29.36%	8,813 $399,000
Q3 2019 Nov 07, 2019	SELL	$35.66 - $44.99 $49,032 - $61,861	-1,375 Reduced 16.79%	6,813 $259,000
Q2 2019 Aug 06, 2019	SELL	$36.57 - $47.97 $426,954 - $560,049	-11,675 Reduced 58.78%	8,188 $356,000
Q1 2019 May 06, 2019	SELL	$36.47 - $42.17 $120,278 - $139,076	-3,298 Reduced 14.24%	19,863 $756,000
Q4 2018 Feb 11, 2019	BUY	$41.31 - $52.16 $956,780 - $1.21 Million	23,161 New	23,161 $996,000
Q3 2018 Nov 14, 2018	SELL	$32.85 - $52.0 $709,921 - $1.12 Million	-21,611 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$27.5 - $39.8 $105,875 - $153,230	3,850 Added 21.68%	21,611 $693,000
Q1 2018 May 14, 2018	SELL	$29.98 - $46.35 $1.53 Million - $2.36 Million	-50,930 Reduced 74.14%	17,761 $553,000
Q4 2017 Feb 14, 2018	BUY	$31.85 - $46.95 $70,579 - $104,041	2,216 Added 3.33%	68,691 $3.14 Million
Q3 2017 Nov 13, 2017	BUY	$35.7 - $39.5 $1.49 Million - $1.64 Million	41,630 Added 167.56%	66,475 $2.5 Million
Q2 2017 Aug 14, 2017	BUY	N/A	24,845	24,845 $1.19 Million

Others Institutions Holding PCRX

# of Institutions

260

Shares Held

49.5M

Call Options Held

1.03M

Put Options Held

139K

Black Rock Inc. New York, NY

8.01M
Shares

$208 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

5.26M
Shares

$137 Million
0.0% of portfolio
Pacer Advisors, Inc. Malvern, PA

3.26M
Shares

$84.8 Million
0.15% of portfolio
D. E. Shaw & Co., Inc. New York, NY

2.26M
Shares

$58.7 Million
0.03% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

1.99M
Shares

$51.8 Million
0.06% of portfolio

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $1.19B
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account